logo-loader

RedHill Biopharma confident about Covid 19 oral pill progress

Published: 07:28 10 Jun 2021 EDT

Newsflow relating to Covid 19 vaccinations is plentiful, but what of potential treatments in the form of oral medication?

Nasdaq-listed RedHill Biopharma (NASDAQ:RDHL) is involved in that search. As chief business officer Guy Goldberg explains to Proactive London's Sarah Lowther the company is confident it may soon have a new weapon in the fight against the pandemic. 

The biopharmaceutical company has completed the enrollment of its oral Opaganib phase 2/3 COVID-19 Study. The primary endpoint of the study, says RedHill, is the proportion of patients breathing room air without oxygen support by Day 14.

Immunic Therapeutics reaches major milestone with completion of ENSURE Trial...

Immunic Therapeutics Chief Medical Officer Dr Andreas Muehler joined Steve Darling from Proactive to announce two major developments for the company’s lead drug candidate, vidofludimus calcium (IMU-838)—a nuclear receptor-related 1 (Nurr1) activator currently being investigated for the treatment...

2 days, 11 hours ago
OSZAR »